HOPA 2018 | Immunotherapy options for NSCLC: nivolumab, pembrolizumab or atezolizumab?

Ross Camidge

How do you decide on which drug to use when treating non-small cell lung cancer (NSCLC) patients in a second-line setting? Here, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO addresses the question of how to choose between nivolumab, pembrolizumab and atezolizumab for the treatment of NSCLC.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter